Citation

The objective was to develop microspherebased delivery systems (MDS) for controlled and pulsed-release delivery of recombinant anthrax vaccine via intranasal immunisation. Microsphere-based recombinant protective antigen (RPA) delivery systems for intranasal immunisation were successfully developed, wherein the MDS formulations produced extremely high antibody titres (over 150,000) in mice after 65 days of immunisation compared with the aqueous RPA vaccine system (at 15,900). Selected MDS systems were challenged with anthrax toxin. The MDS systems, on two intranasal doses, showed 100% protection against anthrax toxin challenge in mice, compared with